Table 1.
Baseline characteristics of included studies.
| Number of HF patients | SGLT2 inhibitor | Female, n(%) | Mean/ median age (years) | Black, n(%) | HFpEF, n(%) LVEF criteria | Diabetes, n(%) | Mean/median eGFR (mL/min/1·73m2) | NYHA II, n(%) | NYHA III/IV, n(%) | Follow-up (months) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| de Boer 2020 [29] | 63 | empagliflozin | 24 (38·1) | 70 | 1 (1·6) | 48 (76·2) LVEF ≥45% | 63 (100) | NA | 47 (74·6) | 16 (25·4) | 3 |
| CANVAS HF 2018 [9,28] | 1461 | canagliflozin | 648 (44·3) | 63·8 | 28 (1·9) | NA | 1461 (100) | 73·0 | NA | NA | 47 |
| CREDENCE 2019 [26,27] | 652 | canagliflozin | 257 (39·4) | 65·2 | 27 (4·1) | NA | 652 (100) | 57·0 | 359 (55·1) | 70 (10·7) | 31·4 |
| DAPA-HF 2019 [8,30] | 4744 | dapagliflozin | 1109 (23·3) | 66·3 | 226 (4·7) | 0 | 1983 (41·8) | 65·7 | 3203 (67·5) | 1541 (32·5) | 18·2 |
| DECLARE- TIMI 58 2019 [10,17] | 1724 | dapagliflozin | 37·4%* | 63·9* | 3·5%* | 808 (46·9) LVEF ≥45% | 1724 (100) | 85·2* | 1114 (64·6) | 154 (8·9) | 50·4 |
| DEFINE-HF 2019 [24] | 263 | dapagliflozin | 70 (26·6) | 61·3 | 99 (37·6) | 0 | 166 (63·1) | 69 | 173 (65·6) | 90 (34·2) | 3 |
| EMPA-REG OUTCOME 2015 [11,25] | 706 | empagliflozin | 211 (29·9) | 64·5 | 357 (5)* | NA | 706 (100) | 65·2 | NA | NA | 37·2 |
| EMPA-TROPISM 2020 [23] | 84 | empagliflozin | 30 (35·7) | 62 | 16 (19) | 0 | 0 | 81·5 | NA | NA | 6 |
| EMPEROR-Reduced 2020 [12] | 3730 | empagliflozin | 893 (23·9) | 66·8 | 257 (6·9) | 0 | 1856 (49·7) | 62 | 2800 (75) | 930 (24·9) | 16 |
| EMPIRE HF 2020 [22] | 190 | empagliflozin | 28 (14·7) | 64 | NA | 0 | 24 (12·6) | 74 | 149 (78·4) | 29 (15·2) | 3 |
| REFORM 2020 [21] | 56 | dapagliflozin | 19 (33·9) | 67·1 | NA | NA | 56 (100) | 72 | 24 (42·9) | 7(12·5) | 12 |
| SCORED 2020 [13] | 3283 | sotagliflozin | 44·9%* | 69* | 364 (3·4)* | 1667 (50·7) LVEF ≥50% | 3283 (100) | 44·5* | NA | NA | 16 |
| SOLOIST-WHF 2020 [14] | 1222 | sotagliflozin | 412 (33·7) | 70 | 50 (4) | 256 (20·9) LVEF ≥50% | 1222 (100) | 49·7 | 552 (45·1) | 614 (50·2) | 9 |
| SUGAR-DM-HF 2020 [20] | 105 | empagliflozin | 28 (26·6) | 68·7 | NA | 0 | 82 (78·1) | 67·3 | 81 (77·1) | 24 (22·9) | 9 |
| VERTIS 2020 [15,16] | 1958 | ertugliflozin | 624 (31·8) | 64·4* | 235 (2·8)* | 1007 (51·4) LVEF >45% | 1958 (100) | 76* | 1289 (95·8) | 140 (7·1) | 42 |
*Data in the entire study population, not just in patients with heart failure; eGFR: estimated glomerular filtration rate; HF: heart failure; HFpEF: heart failure with preserved ejection fraction; LVEF: left ventricular ejection fraction; NA: not available; NYHA: New York Heart Association functional classification; SGLT2i: sodium-glucose co-transporter 2.